Andere talen PharmaEssentia Corporation

Aandelen

6446

TW0006446008

slotkoers Taiwan S.E. Andere beurzen 00:00:00 26-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
285,5 ^TWD	-1,04%		0,00%	-17,49%

26/04	PharmaEssentia Corp. dient Fase III Klinisch Studieprotocol van P1101 voor pre-fibrotische/ vroege PMF of overmatige PMF met laag tot gemiddeld-1 risico in bij de Chinese NMPA	CI
24/04	PharmaEssentia Corp. Kondigt de indiening aan van de vergunningaanvraag voor het in de handel brengen van BESREMi (Ropeginterferon alfa-2B) voor PV in Colombia	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

PharmaEssentia Corp. Submits Phase III Clinical Study Protocol of P1101 for Pre-fibrotic/ Early PMF or OvertPMF at Low to Intermediate-1 Risk to China NMPA	26/04
PharmaEssentia Corp. Announces Submission of Marketing Authorization Application of BESREMi (Ropeginterferon alfa-2B) for PV in Colombia	24/04
PharmaEssentia Corporation cancelled the transaction announced on April 2, 2024	16/04
PharmaEssentia - ANALYSES FIND PATIENTS WITH POLYCYTHEMIA VERA TREATED WITH BESREMI HAD INCREASED PROBABILITY OF ACHIEVING COMPLETE HEMATOLOGIC RESPONSE	02/04
PharmaEssentia Corporation announced a financing transaction	02/04
PharmaEssentia Corp. Announces Submission of Marketing Authorization Application of BESREMi (Ropeginterferon Alfa-2b) for PV in Brazil	28/03
PharmaEssentia Corporation Updates on IND Application of Phase I Clinical Trial of Sequential Treatment of P1801 Following P1101 in Patients with Advanced Solid Tumors to TFDA	04/03
PharmaEssentia Corporation Submits IND Application of Phase I Clinical Trial of P2203 to Taiwan Food and Drug Administration	04/03
PharmaEssentia Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	27/02
PharmaEssentia Corporation(TWSE:6446) added to Taiwan TAIEX Index	19/02
Soleno Therapeutics Names Meredith Manning as Chief Commercial Officer	24/01
PharmaEssentia Corporation Submits Phase III Clinical Study Protocol of P1101 for Pre-Fibrotic/Early PMF or Overt PMF At Low to Intermediate-1 Risk to U.S. FDA	17/01
PharmaEssentia Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	10/11
Presentations at MPN Congress and ASH Annual Meeting Reinforce Clinical Role of ropeginterferon alfa-2b-njft	02/11
PharmaEssentia Corporation Announces Enrollment Completion of Phase III Clinical Trial of Ropeginterferon alfa-2b for Essential Thrombocythemia	25-10-23
PharmaEssentia Enters Into Exclusive Global License Agreement With WuXi Biologics for a Myeloid Immune Checkpoint Antibody Candidate	03-10-23
Pharmaessentia Corporation Enters into Exclusive Global License Agreement with Wuxi Biologics for A Myeloid Immune Checkpoint Antibody Candidate	03-10-23
Tranche Update on PharmaEssentia Corporation's Equity Buyback Plan announced on July 28, 2023.	28-09-23
PharmaEssentia Corporation's Equity Buyback announced on July 28, 2023, has closed with 4,000,000 shares, representing 1.19% for TWD 1,351.42 million	28-09-23
Pharmaessentia Corp. Announces 52-Week Result of the Phase II Clinical Trial of Ropeginterferon Alfa-2B for the Treatment of PV in China	20-09-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen PharmaEssentia Corporation

Aandelen

6446

TW0006446008

Andere talen

Filters